Cart
sales@molnova.com
Ponsegromab
CAS No. 2368950-15-4
Ponsegromab( —— )
Catalog No. M36709 CAS No. 2368950-15-4
Ponsegromab (PF 06946860) is a selective and effective humanized anti-GDF15 antibody inhibitor with anti-cachexic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 662 | In Stock |
|
| 10MG | 1064 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePonsegromab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPonsegromab (PF 06946860) is a selective and effective humanized anti-GDF15 antibody inhibitor with anti-cachexic activity.
-
DescriptionPonsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGF-beta/Smad
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2368950-15-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. E.J. Roeland, et al. 1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. VOLUME 32, SUPPLEMENT 5, S1185, SEPTEMBER 01, 2021. Annals of oncology.
molnova catalog
related products
-
DL-Tartaric acid
DL-Tartaric acid is a natural product.
-
2-Amino-6-(methylsul...
2-Amino-6-(methylsulfonyl)benzothiazole is identified as a new development of improved pteridine reductase-1 (PTR1) inhibitors and anti-trypanosomatidic agents.
-
Esculentoside A
Esculentoside A can suppress inflammatory responses in LPS-induced ALI through inhibition of the NF-κB and mitogen-activated protein kinase signaling pathways.
